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KEY POINTS
 Advent and implementation of stent retrievers has revolutionized the management of ischemic
strokes caused by large vessel occlusion (LVO).
 Patient selection is complex. Salient variables for case selection include patient age, prestroke
disability, National Institutes of Health Stroke Scale score, LVO territory/location, and time of
presentation from symptom onset.
 Quality of reperfusion after the first pass of mechanical thrombectomy is associated with better
outcomes.

INTRODUCTION
Acute ischemic stroke (AIS) remains one of the
major causes of death worldwide and a leading
cause of disability. Historically, stroke care has
been very challenging, and only recently has major progress been made in improving neurologic
outcomes and reducing mortality. A major
obstacle to advances in stroke care has been
the delayed recognition of stroke symptoms by
the lay public as well as clinicians. In addition,
the risk of intracranial hemorrhage (ICH) due to
revascularization therapies has been the major
hurdle to improving stroke outcomes. It is the
most feared complication of AIS therapy and
when it occurs in this setting it is often catastrophic and essentially untreatable. This risk
was very high with early trials of a variety of
thrombolytic agents. It was not until 1995 that
the first proven treatment of AIS, intravenous tissue plasminogen activator, was confirmed. That
treatment was of marginal benefit, and it would
take another 20 years before a highly effective
treatment of the most severe strokes, large
vessel occlusions (LVO), would be validated.
This endovascular therapy (EVT), also known as

mechanical embolectomy, requires the prompt
recognition of stroke symptoms, rapid imaging
of the cerebrum and the cerebral vasculature
often with advanced imaging of the ischemic
penumbra. Once the appropriate patient is
selected to minimize the risk of ICH and maximize the potential benefit, then treatment must
be initiated quickly to reduce stroke morbidity
and mortality.

LARGE VESSEL OCCLUSION, DEFINITION,
AND PATHOPHYSIOLOGY
AIS due to LVO is defined as the abrupt neurologic dysfunction caused by a disruption of the
arterial blood supply by an occlusion of a cervical
or intracranial artery. This occlusion can be in the
anterior circulation (ie, internal carotid territory)
or posterior circulation (ie, vertebra-basilar territory). LVO accounts for about 30% of all AIS.1
Cause of LVO can be cardioembolic, thromboembolic (ie, artery to artery), atherosclerotic
with in-situ thrombosis, and lastly cryptogenic
when no clear cause is identified. The management approach is generally the same in the
acute phase regardless of the cause.
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CLINICAL PRESENTATION AND EARLY
DETECTION
In LVO stroke, every 1 minute of ischemia destroys about 1.9 million neurons and 14 billion
synapses2; this makes early recognition and
prompt revascularization crucial. Recognition of
LVO strokes starts in the prehospital setting
with emergency medical services. Various scores
have been developed to help recognize LVO
stroke and categorize its severity. These scores
can facilitate communication with stroke centers
before arrival. Although many scores have been
developed, none have been shown to be superior to others and they all share a focus on the
presence of motor and cortical symptoms.
Regardless of the score used, LVO stroke should
be suspected when a patient shows cortical
signs (Box 1). The presence of cortical signs is
a good indicator for anterior circulation LVO
stroke in the prehospital as well as in-hospital
setting.3 The detection of posterior circulation
strokes remains challenging due to their relative
rarity (approximately 10% of LVO) but also due
to the myriad clinical symptoms as well as the
higher likelihood of slow clinical progression
and alteration of consciousness, which can often
be
misdiagnosed
as
“confusion”
or
“encephalopathy.”

PATIENT SELECTION AND IMAGING IN
THE ACUTE PHASE
All patients presenting with strokelike symptoms
should undergo a computed tomography (CT)
scan of the head without contrast to exclude
ICH. The presence of ICH is generally a contraindication to revascularization therapy for AIS.
Often LVO can be suspected on clinical grounds
if there are signs of cortical ischemia or a high
National Institutes of Health Stroke Scale
(NIHSS)—the latter is the standard research
and clinical scale for defining stroke severity.
The scale gives patients points for deficits, and
the score can range from 0 for patients who
are nearly normal to 42 for those who are comatose and moribund. A score of 7 or more has
been found to have a positive predictive value
for LVO of 84.2%.4 The higher the score, the
more severe the stroke and the greater the
thrombus burden. On imaging with CT head
without contrast, a hyperdense vessel sign can
be seen, and this can also suggest the presence
of an LVO (Fig. 1). However, the gold standard
for acute phase confirmation of LVO is CT angiography (CTA) of the head and neck, which is
used to select the most appropriate candidates

for EVT. A recent single-center study revealed
increase in LVO detection with performing CTA
for all patients presenting with strokelike symptoms with decrease in the door to groin time
and a signal toward favorable clinical outcomes.5
Furthermore, head and neck vessel imaging
have been the standard of care for stroke etiology workup. Hence, our practice has been to
perform CTA head and neck in addition to CT
head in the acute phase for all patients presenting with strokelike symptoms. An alternative
approach in case of limited resources is to
perform CTA only for patients with high suspicion for LVO such as those with a high NIHSS.
The American Heart/Stroke Association (AHA/
ASA) guidelines for endovascular treatment of
LVO recommends that the NIHSS be 6 or higher.
Patients with LVO in the posterior circulation
may not show cortical signs/symptoms but
rather cranial nerve deficits, motor symptoms,
and/or decreased level of alertness.
In addition to the aforementioned criteria,
many other clinical criteria must be considered
in deciding who is a candidate for revascularization therapy. Baseline blood pressure, glucose
levels, the use of anticoagulants, recent stroke
symptoms or neurosurgical procedures, baseline
cognitive function and level of independence,
age, and many others may all affect the risk of
ICH with revascularization as well as the potential for clinical benefit. More controversial is the
use of advanced imaging techniques such as
perfusion imaging to determine eligibility. CT
perfusion (CTP) imaging is the most commonly
used and is able to determine the presence of
a completed infarct (infarct core) as well as regions of critical hypoperfusion, which are still
salvageable (ischemic penumbra). Proponents
feel that CTP imaging increases the probability
of identifying patients who would benefit from
treatment, as revascularization of a completed
infarct is of no benefit to the patient and only increases the risk of harm. Opponents of CTP
argue that the time delay in obtaining and interpreting the studies is unnecessary and only
serves the purpose of excluding patients from
treatment. They feel a clinical-CT mismatch (ie,
a severe clinical deficit with no to minimal signs
of early infarct on CT) is comparable to CTP imaging. This issue is currently unresolved but it is
hoped that ongoing clinical trials would bring
clarity soon.
More recently multiple artificial intelligence
software platforms have been developed for
the automatic detection of LVO and CTP deficits. Several have received Food and Drug
Administration (FDA) approval for clinical use.
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Box 1
Cortical Signs and Symptoms
Gaze deviation
Homonymous hemianopsia
Aphasia
Neglect

These platforms can be installed on the CT scanner and within minutes of image acquisition can
send out email and smart phone notifications of
the presence of an LVO. Although not perfect,
their sensitivity and specificity are high enough
(>80% for both) that they are increasingly
becoming the standard means of LVO and
ischemic penumbra detection especially when
specialized neuroradiological interpretation is
not emergently available.

THROMBOLYSIS THERAPY
Recombinant Tissue Plasminogen Activator
Intravenous recombinant tissue plasminogen
activator (rtPA) remains the standard of care
for patients presenting with AIS within 3 to
4.5 hours of symptom onset including patients
with LVO. The use of intravenous (IV) tPA is
limited to patients who meet specific and extensive criteria aimed at minimizing the risk of ICH.
It is dosed 0.9 mg/kg with a maximum dosage of

Fig. 1. Circle pointing out a hyperdense left middle
cerebral artery suggesting an occlusion.

90 mg; 10% is given as a bolus, and the
remainder is infused over 1 hour. rtPA is most
effective in patients presenting within 60 minutes
of symptom onset and in those with a smaller
thrombus burden. The site and size of the
thrombus influences recanalization rates after
rtPA with more proximal occlusions, for
example, internal carotid artery, the least likely
to recanalize.6–8 As with facilitated thrombolysis
in patients with ST segment elevation myocardial infarction there has been debate as to
whether IV thrombolysis is of utility in the modern era of EVT. Two trials from China and Japan
(DIRECT-MT, SKIP) demonstrated noninferiority
of EVT with mechanical thrombectomy (MT)
alone compared with MT plus intravenous rtPA
for functional outcome. However, DIRECT-MT
did show that MT alone was associated with
significantly lower recanalization. Conversely,
combination treatment showed higher rates of
symptomatic ICH.9,10 A meta-analysis of 30
studies showed better clinical outcomes, lower
mortality at 90 days, and higher successful
recanalization rates, without increasing the risk
of hemorrhagic complications with combination
therapy.11 Because EVT is not always feasible
or can fail to reach the site of occlusion, in keeping with AHA/ASA guidelines, our practice has
been to administer rtPA to all those who qualify
in combination with MT, especially if the patient
is being transferred from a primary stroke center
to a thrombectomy capable center.12

Tenecteplase
The use of tenecteplase in AIS remains a hot
topic for discussion, given that IV rtPA is the
only FDA-approved treatment of AIS to date.
Tenecteplase, a genetically engineered mutant
form of rtPA has been studied as a possible
alternative to rtPA because of its longer halflife and higher fibrin specificity; the latter may
be associated with lower risks of bleeding. It is
also more convenient to administer as an intravenous single bolus as compared with rtPA
that requires a bolus followed by an hour-long
infusion. A meta-analysis of the major trials
(ATTEST and EXTEND-IA TNK) in patients with
LVOs showed higher odds of successful recanalization and good functional outcomes with tenecteplase compared with rtPA.13 Although the
optimal dose of tenecteplase for AIS remains unknown, current AHA/ASA guidelines consider
tenecteplase (0.25 mg/kg dose with a maximum
dose of 25mg) a reasonable alternative for patients undergoing thrombectomy.12 TNK-S2B
trial is currently enrolling to identify the optimal
dose of tenecteplase with comparison to rtPA.
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MECHANICAL THROMBECTOMY
Initial approaches to the endovascular treatment
of AIS consisted of intraarterial thrombolysis
with marginal clinical benefits and high complication rates.14,15 The first FDA-approved device
for AIS treatment was the MERCI (Concentric
Medical Inc., CA, USA) retriever device of the
early 2000s followed by the and Penumbra Inc.
aspiration system. Although both devices had
variable success in cerebral thrombectomy,
these systems failed to show superiority over IV
rtPA alone in 3 different trials published in
2013 (IMS-III, MR RESCUE, SYNTHESIS).14–16 A
breakthrough in the management for LVO stroke
was the advent of the so-called stent retrievers.
These devices consist of self-expanding (nitinol)
stents permanently attached to 0.01400 wires.
They are deployed within the occlusion/
thrombus and removed a few minutes later after
the thrombus has been integrated within their
interstices. They are often used with a balloon
occlusion guide catheter, which is used to
occlude antegrade flow and permit the creation
of a suction effect while the device is removed,
facilitating thrombus removal.
MT has been studied primarily in patients with
anterior circulation LVO. The anterior circulation
includes the internal carotid (ICA), middle cerebral (MCA), and anterior cerebral arteries
(ACA). The posterior circulation includes the
vertebral, basilar (BA), and posterior cerebral
arteries.

PATIENT SELECTION FOR MECHANICAL
THROMBECTOMY IN ANTERIOR
CIRCULATION LARGE VESSEL OCCLUSION
Based on the available clinical trials, careful selection of patients for mechanical thrombectomy
is crucial for good outcomes. The following aspects must be taken into consideration when
selecting patients:

Age Less Than or Equal to 18 Years
The available randomized controlled trials
included patients who were 18 years and older.
However, good neurologic outcome has been
reported in case series and meta-analysis of pediatric age group who received mechanical
thrombectomy.17 In its recent report the Society
of Neurointerventional Surgery recommends
against withholding mechanical thrombectomy
from the pediatric age group.18 On the other
end of the spectrum, the very old (90 years
and older) do not have as good of outcomes
as younger patients; however, all studies have
shown a consistently high relative benefit for

this population mostly because lack of recanalization is associated with almost uniformly poor
outcomes.

Prestroke Disability
Good baseline functional status prestroke was
one of the inclusion criteria for most of the clinical trials in the early and extended time windows; this was defined as a Modified Rankin
Scale (mRS) score of 0 or 1 (Table 1), that is, patients with moderate or severe disabilities were
excluded. Data from good, randomized trials
are lacking for this patient population. Retrospective studies have shown mixed results in
terms of good outcomes or return to baseline.19,20 AHA/ASA guidelines support treatment of patients with independent baseline
function, that is, mRS 0 to 1, despite this mechanical thrombectomy should not be withheld
blindly for patients with moderate to severe
disability, that is, mRS of 2 to 4. Our practice it
to assess on a case-by-case basis and to confer
with the patient’s family.
NIHSS at Presentation
Most of the MT trials enrolled patients with
NIHSS greater than or equal to 6, which is generally considered to be disabling. The efficacy of
MT in patients with NIHSS less than 6 remains
under investigation. Our practice is to offer MT
based on the severity of deficits and resultant
disability regardless of NIHSS, taking into account unique patient characteristics, for
example, an isolated homonymous hemianopsia
would result in an NIHSS of 2 but this deficit in a
young aircraft pilot would be a career ending
deficit but may not affect the life of an octogenarian as severely.
Location of the Large Vessel Occlusion in the
Anterior Circulation
In the anterior circulation, most of the clinical trials included patients with ICA and proximal
MCA trunk (M1) occlusion (Fig. 2). Patients
with more distal MCA trunk or MCA branch occlusions (first-order branches in the Sylvian
fissure are referred to as M2 segments) or occlusions of other vessels such as the ACA were
either excluded or underrepresented. Hence
the data available for safety and efficacy are
applicable to distal ICA or proximal MCA LVO.
The current AHA/ASA guidelines recommend
limiting treatment to those vessels only. Pooled
data from multiple series of MT patients with
M2 occlusions have revealed generally good
functional outcomes with reperfusion (mRS 0–1;
OR 2.2, 95% confidence interval [CI] 1.0–4.7).21
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The major concern is that more distal occlusions
tend to involve smaller vessels (<2 mm), which
are associated with lower NIHSS scores and
which are also more angulated, all of which
may be associated with higher risks of ICH and
lower net benefit. Our practice for LVO involving
the distal M1, M2 branches, and the proximal
ACA segments is to assess patients on a caseby-case basis and to offer MT only if deficits
are disabling and the occlusion can be reached
safely using available equipment.

Presentation 6 Hours or Less from Last
Known Well (Early Window)
Six clinical trials published in 2015 compared MT
with stent retrievers with intravenous rtPA alone
or best medical therapy. These trials established
the superiority of MT in patients presenting
within 6 hours with a number needed to treat
(NNT) to achieve functional independence
ranging from 3 in the EXTEND-IA22 trial to
NNT of 7.5 in MR CLEAN trial.23 A pooled
meta-analysis of 5 of the clinical trials was performed by the HERMES collaboration and
revealed an NNT of 2.6 to reduce disability by
at least 1 grade on mRS. Patient’s eligibility for
MT mainly depends on the Alberta Stroke Program Early CT Score (ASPECTS). This is a 10point score of the extent of infarction in the
MCA territory on axial CT head or diffusionweighted MRI. A score of 10 indicates no signs
of early ischemia in the MCA territory, whereas
a score of 0 indicates complete MCA early
ischemic changes. Good outcome with mechanical thrombectomy was seen in patients with ASPECTS of greater than or equal to 6. Patients
with ASPECTS less than 6 have less benefit and
increased risk from mechanical thrombectomy,
although it is not clear that the benefit of MT
in low ASPECTS patients is not clinically meaningful. It is important that the ASPECTS be
considered in the overall clinical context with
the age of the patient, baseline level of independence, and patient/family preferences regarding
goals of care in the setting of certain disability.

Fig. 2. Arrow points to right MCA proximal M1
segment occlusion.

Presentation 6 to 24 Hours from Last Known
Well (Late Window)
The AHA/ASA time window recommendations
for MT were expanded to 16 hours after the results of the DEFUSE trial were published24 and
to 24 hours after the results of the DAWN25 trial
were published. Both DEFFUSE and DAWN
selected patients for MT by using advanced imaging with CTP or MR perfusion. Both trials used
the concept of infarct core (IC) to penumbra
mismatch on perfusion imaging measured by
automated software. Core infarct was defined
equally in both trials as cerebral blood flow
(CBF) less than 30% of the contralateral normal
hemisphere CBF, whereas the penumbra was
defined by a Tmax greater than 6 seconds, which
is a region of reduced perfusion that was not yet
included in the infarct core (Fig. 3).
DEFFUSE 3 enrolled patients up to 90 years
of age with NIHSS greater than or equal to 6
and presenting within 6 to 16 hours of last
known well. The trial required that the IC volume
be less than 70 mL and an IC:penumbra

Table 1
Modified Rankin Scale (mRS)
0 No symptoms
1 No significant disability despite symptoms.
Able to carry out all usual activities and
duties
2 Slight disability, unable to carry out all
previous activities but able to look after
own affairs without assistance
3 Moderate disability, requiring some help
but able to walk without assistance
4 Moderately severe disability; unable to walk
and attend to bodily needs without
assistance
5 Severe disability, bedridden, incontinent,
and requiring constant nursing care and
attention
6 Dead
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Furthermore, some have questioned the need
for such strict imaging criteria, which can delay
and restrict the number of patients treated; to
address this issue there are several RCTs that
are assessing the benefit of MT in patients with
larger IC or ASPECT less than 6.

POSTERIOR CIRCULATION LARGE VESSEL
OCCLUSION

Fig. 3. Circle showing stent retriever deployed in the
right middle cerebral artery.

mismatch of greater than 1.8. The trial was
stopped early after enrollment of 182 patients
due to efficacy of the treatment arm. Functional
independence defined as mRS of 0 to 2 at
90 days was achieved in 44.6% in the mechanical
thrombectomy arm compared with 16.7% in the
medical treatment arm with (P < .001). The number NNT to achieve functional independence
was 3.6.
The DAWN trial enrolled 206 patients between 6 and 24 hours from stroke onset with a
more complex clinical and radiographic
mismatch criteria. Penumbra was not directly
assessed but was inferred based on clinical:IC
mismatch: patients were categorized into 3
groups:
Group A: patients aged 80 years and older
with NIHSS greater than or equal to 10 and
infarct volume less than 21 mL.
Group B: patients younger than 80 years with
NIHSS greater than or equal to 10 and infarct
volume less than 31 mL.
Group C: patients younger than 80 years with
NIHSS greater than or equal to 20 and infarct
volume 31 to 51 mL.
Functional independence defined as mRS of
0 to 2 at 90 days was achieved in 49% in the
MT arm compared with 13% in the medical
arm. The NNT was 3. The rate of symptomatic
ICH was not significantly different (6% with MT
vs 3% with medical treatment, P 5 .5). These 2
trials have significantly changed the paradigm
of acute stroke management in the late window.
Mechanical thrombectomy outside the strict
criteria set by DEFFUSE 3 and DAWN trials in
the late window is considered experimental.

The incidence of LVO in the posterior circulation
including the VA, BA, or posterior cerebral arteries is much lower than in the anterior circulation. On the other hand, acute BA occlusion
carries a higher risk of severe neurologic deficit
and death. The randomized trials of MT did
not include this patient population and as such
the AHA/ASA guidelines did not support MT
with the same level of vigor as in the anterior circulation. Recently the first international RCT
comparing MT with standard medical treatment
in BA occlusion (BASICS) was completed with
disappointing results. MT performed within
6 hours of stroke onset showed no significant
benefit compared with standard medical therapy for 90-day disability. However, the confidence intervals were very wide due to
underrecruitment, and a substantial benefit of
mechanical thrombectomy cannot be excluded
based on this trial. On subgroup analysis there
was a signal of benefit with MT for patients presenting with an NIHSS greater than or equal to
10.26 The optimal patient selection and time window for mechanical thrombectomy in BA occlusion remain unclear. One of the major
challenges is that imaging of the neural structures of the posterior circulation is limited by
bony artifacts with conventional CT. MRI is far
superior for the detection of acute ischemia
but is time-consuming and may not be readily
available. Another limitation of posterior circulation MT trials is that there is a higher prevalence
of atherosclerotic occlusion as the cause of the
LVO compared with anterior circulation trials
that may be associated with less desirable angiographic outcomes and a higher rate of reocclusion with MT performed without angioplasty
and stenting. Our current practice is to offer
MT to patients with significant disability or
NIHSS greater than 10 who do not have evidence of extensive pontine, midbrain, or
thalamic infarction. If possible, we will perform
a limited MRI, so called “wake-up MRI protocol,” for patients presenting beyond 6 hours to
rule out irreversible infarction of the brain stem
before revascularization. Further studies with
larger number of subjects are needed.
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REPERFUSION AND FIRST PASS EFFECT
The main goal in acute stroke treatment is to
achieve complete reperfusion to the affected
area of the brain as soon as possible. The modified Thrombolysis in Cerebral Infarction (mTICI)
score (Table 2) is the most widely used score
across all MT trials that quantify reperfusion angiographically. TICI score is proved to predict
outcomes. TICI 2b and higher is considered
adequate reperfusion that is associated with
improved outcomes in most of the clinical trials,
although more recently it is recognized that the
goal of MT should be TICI 2c or 3. In some cases,
multiple passes of the stent retriever are needed
to achieve reperfusion, and this is associated
with higher rates of complications and futility.
Achievement of reperfusion after a single stent
retriever pass is associated with significantly better outcomes and is known as the first pass effect. The usage of balloon guide catheters
(BGC) during MT is associated with increased
first pass effect.27

STENT RETRIEVER VERSUS SUCTION
THROMBECTOMY (THE COMPASS TRIAL)
MT can be performed using second-generation
stent retrievers, distal aspiration catheters, or
both together. The COMPASS trial randomized
270 patients with anterior circulation LVO to
MT using catheter aspiration (AKA contact aspiration) only or stent retriever as first-line treatment. There was no difference in good
functional outcomes at 90 days between the 2
groups with similar recanalization rates, indicating noninferiority of aspiration thrombectomy. Achievement of TICI 3 within 45 minutes
was better with aspiration technique (34% vs
23%, P 5 .05), and time to groin puncture was
shorter compared with patients treated with a
stent retriever (25 minutes vs 35 minutes,
P 5 .03).28 However, a minority of the stent
retriever procedures were performed with BGC
catheters, which casts doubt on the validity of
the comparison. There were no significant differences in rates of ICH, all-cause mortality, or
overall safety. More recently the ASTER 2 trial
conducted in France29 showed that contact aspiration combined with a stent retriever had
similar rates of TICI 2c/3 and clinical outcomes
to stent retrievers with BGC catheter. The current AHA/ASA guidelines acknowledge noninferiority of contact aspiration. Our approach is
to use stent retrievers and BGC catheters as
first-line treatment except in cases of severe cervical tortuosity, dissection, or stenosis that may

Table 2
Modified thrombolysis in cerebral infarction
(mTICI) score
mTICI 0

No recanalization

mTICI 1

Minimal recanalization

mTICI 2a

Partial recanalization and
perfusion of < 50% of the
vessel territory

mTICI 2b

Partial recanalization perfusion
of > 50% of the vessel
territory

mTICI 2c

Near-complete perfusion
except for slow flow in a few
distal cortical vessels or
presence of small distal
cortical emboli

mTICI 3

Complete reperfusion

preclude distal placement of the BGC, in which
case we use contact aspiration along with a stent
retriever.

GENERAL ANESTHESIA VERSUS
CONSCIOUS SEDATION
Mechanical thrombectomy can be performed
under general anesthesia (GA) or conscious
sedation (CS). Several retrospective studies
have shown that CS may be associated with better outcomes and lower mortality than GA.30,31
Although GA leads to better control over patient movements, making it more comfortable
for both patient and operator, it may add to
the time of procedure initiation, carries the risk
of significantly dropping blood pressure during
induction, and masks the pain response associated with cerebral vessel stretching, vasospasm,
and injury. On the other hand, CS may be associated with a higher risk of aspiration in some patients. Three small sample size randomized
single-center trials (AnSTROKE, SIESTA, and
GOLIATH) have shown noninferiority of GA
compared with CS in clinical outcomes.32–34
Because of the discrepancy between the very
large retrospective analyses and the smaller
RCTs, larger RCTs are being conducted. Until
further conclusive evidence is available, we
recommend individualizing anesthesia choice
based on a patient’s status. GA is preferred for
severely agitated patients or those who are
comatose and unable to maintain their airway.
It is critical that drops in blood pressure be
avoided during induction and maintenance of
GA or CS.
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BLOOD PRESSURE MANAGEMENT
POSTMECHANICAL THROMBECTOMY
Hypertension is a well-known physiologic
response to brain ischemia as part of cerebral
autoregulation, which can maximize CBF via collaterals despite LVO. Blood pressure (BP) goals
before and during MT should be to maintain
BP at baseline unless it is very high (systolic
BP > 220 mm Hg) or low (<130 mm Hg). BP
goals after MT have been a topic of controversy.
Good evidence data from RCTs are not yet available. The best available evidence comes from a
multicenter retrospective study showing a
higher likelihood of good outcome and lower
odds of hemicraniectomy in the group of patients with systolic blood pressure less than
140 mm Hg after successful recanalization.35
Very elevated BP after MT has been associated
with poor outcomes but so has very low BP
resulting in a U-shaped curve.36,37 Higher SBP
targets can be considered on a case-by-case basis in patients who achieve partial recanalization
in order to maintain perfusion to the tissue at
risk. Regardless of BP goal, close observation
in dedicated stroke units or neurologic critical
care units by dedicated nurses and physicians
is essential and has been associated with
improved neurologic outcomes.38
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